Context Therapeutics Showcases CT-95 and CT-202 Initiatives at SITC Conference
Context Therapeutics shared two posters discussing the Company's CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's 40th Annual Meeting, being held November 7-9, 2025 in National Harbor, MD. CT-95: Mesothelin x CD3 bispecific TCE: CT-95 is avidity enhanced and affinity tuned to localize therapeutic activity to the tumor microenvironment. In an ongoing Phase 1 trial, Context has enrolled 6 patients as of the October 30, 2025 cutoff, and is currently enrolling Cohort 3 with a priming dose of 0.18 microgram/kg and a full dose of 0.6 microgram/kg. Based on preclinical data, CT-95 is projected to achieve target dose exposure starting at Cohort 4. No cytokine release syndrome greater than Grade 2 has been observed in any cohort. No dose limiting toxicity has been observed and a maximum tolerated dose has not been reached. Based on this safety profile, we are continuing dose escalation for CT-95 toward target dose levels. Context anticipates providing initial Phase 1a data in the middle of 2026. CT-202: Nectin-4 x CD3 bispecific TCE Preclinical data supports best-in-class potential of CT-202. Demonstrates potent preclinical activity with a favorable pharmacokinetic and safety profile, supporting its expected transition into clinical studies. Expect to complete necessary regulatory filings to support the initiation of a first-in-human trial in the second quarter of 2026.
